An adaptive phase II basket trial design

Size: px
Start display at page:

Download "An adaptive phase II basket trial design"

Transcription

1 Novartis Translation Clinical Oncology An adaptive phase II basket trial design Matt Whiley, Group Head, Early Development Biostatistics BBS / PSI One-day Event on Cancer Immunotherapy Basel 15 June 2017

2 An adaptive phase II basket trial design 1. Trial design overview 2. Bayesian hierarchical model: EXNEX 3. Some design issues 4. Last words 2

3 Bayesian adaptive signal finding BAYESIAN ADAPTIVE SIGNAL FINDING INDICATION A INDICATION B INDICATION C INDICATION D INDICATION E INDICATION F INDICATION G INDICATION H INTERIM ANALYSIS OF ORR USING BAYESIAN ADAPTIVE MODEL N=n 1 / INDICATION UP TON=n 2 / INDICATION 3

4 Bayesian adaptive signal finding Multiple indications Small (initial) sample sizes Initial futility decision after response outcome observed for N=n 1 patients How to make optimal use of available data? 4

5 Bayesian adaptive signal finding Making optimal use of available data Independent strata Each stratum has independent P(response) Pooled Common P(response) 5

6 Bayesian adaptive signal finding Making optimal use of available data Independent strata Each stratum has independent P(response) Exchangeable strata Similar P(response) Hierarchical model allows sharing of information Pooled Common P(response) 6

7 Hierarchical models Increased precision Shrinkage towards common mean 7

8 Hierarchical models Increased precision Shrinkage towards common mean 8

9 EXNEX Mixture of hierarchical and stratified approaches Exchangeable vs Independent is not a dichotomy Each strata is assigned a probability of belonging to the exchangeable group That probability updates as data accumulates Strata initially expected to have similar outcome may prove otherwise Equally, strata initially thought dissimilar may prove to have similar outcome Dynamic borrowing of information between indications More borrowing between indications with similar outcome 9

10 EXNEX Mixture model Exchangeable Non-exchangeable ~ HN 0, ~ N, ~ N, ~ N, 1 log ~, ) 10

11 EXNEX model 11

12 EXNEX model 12

13 Design considerations Exchangeability groups Multiple exchangeability groups are possible 13

14 Design considerations Exchangeability Exchangeability can be defined on: Probability of response Appropriate if we expect to see similar response rates in some or all indications Odds ratio of response More suitable for examples where indications have different historical Hypothesis is to see similar improvement over historical rates 14

15 Design considerations Futility decision making Intention is to make an interim stop/go decision for each indication after n 1 patients have been enrolled At each interim data from all patients is used Futility decision rule applied to each stratum P(π i c i ) > ε 15

16 Design considerations Futility decision making INDICATION A INDICATION B INDICATION C INDICATION D INDICATION E INDICATION F INDICATION G INDICATION H Enrolment rates can vary substantially Only strata reaching a minimum enrolment limit are eligible for closure Strategy for interim futility analyses allowing for: Decisions being taken at the appropriate time Operational feasibility! 16

17 Design considerations Interim decision strategies INDICATION A INDICATION B INDICATION C INDICATION D INDICATION E INDICATION F INDICATION G INDICATION H 1. Trigger an interim as each strata reaches N=n 1 With flexibility to shift decision time points based on projected enrolment 17

18 Design considerations Interim decision strategies INDICATION A INDICATION B INDICATION C INDICATION D INDICATION E INDICATION F INDICATION G INDICATION H 2. Trigger initial interim when first strata reaches N=n 1 Subsequent interims held periodically (e.g. quarterly) 18

19 Last words Flexible, adaptive, signal finding framework Simulation studies demonstrate: Appropriate decision making at interim Good control of overall false positive/negative rates High level of complexity Statistically Operationally 19

20 Acknowledgements Shiling Ruan Simon Wandel Satrajit Roychoudhury Beat Neuenschwander Suman Sen Niladri Roy Chowdhury Stuart Bailey 20

21 Thank you

Becoming a multilingual statistician. Matt Whiley & Stuart Bailey Bayes 2015 Basel

Becoming a multilingual statistician. Matt Whiley & Stuart Bailey Bayes 2015 Basel Becoming a multilingual statistician Matt Whiley & Stuart Bailey Bayes 2015 Basel Novartis Oncology Early Clinical Biostatistics Introduction Novartis Oncology Early Clinical Biostatistics Oncology phase

More information

HIERARCHICAL MODELS A framework for evidence synthesis

HIERARCHICAL MODELS A framework for evidence synthesis HIERARCHICAL MODELS A framework for evidence synthesis Innovative Methodology for Small Populations Research (InSPiRe), WP4 Evidence synthesis Tim Friede Dept. Medical Statistics University Medical Center

More information

Dynamic borrowing of historical data: Performance and comparison of existing methods based on a case study

Dynamic borrowing of historical data: Performance and comparison of existing methods based on a case study Introduction Methods Simulations Discussion Dynamic borrowing of historical data: Performance and comparison of existing methods based on a case study D. Dejardin 1, P. Delmar 1, K. Patel 1, C. Warne 1,

More information

Statistical Challenges in Immunotherapy: Non Proportional Hazard Model. BBS / PSI CIT event 15-June-2017, Basel Claude BERGE, Roche

Statistical Challenges in Immunotherapy: Non Proportional Hazard Model. BBS / PSI CIT event 15-June-2017, Basel Claude BERGE, Roche Statistical Challenges in Immunotherapy: Non Proportional Hazard Model BBS / PSI CIT event 15-June-2017, Basel Claude BERGE, Roche 1 Statistical Challenges Biomarker Efficacy Endpoint Study Design & Analysis

More information

Protocol to Patient (P2P)

Protocol to Patient (P2P) Protocol to Patient (P2P) Ghulam Warsi 1, Kert Viele 2, Lebedinsky Claudia 1,, Parasuraman Sudha 1, Eric Slosberg 1, Barinder Kang 1, August Salvado 1, Lening Zhang 1, Donald A. Berry 2 1 Novartis Pharmaceuticals

More information

Basket and Umbrella Trial Designs in Oncology

Basket and Umbrella Trial Designs in Oncology Basket and Umbrella Trial Designs in Oncology Eric Polley Biomedical Statistics and Informatics Mayo Clinic Polley.Eric@mayo.edu Dose Selection for Cancer Treatment Drugs Stanford Medicine May 2017 1 /

More information

Using mixture priors for robust inference: application in Bayesian dose escalation trials

Using mixture priors for robust inference: application in Bayesian dose escalation trials Using mixture priors for robust inference: application in Bayesian dose escalation trials Astrid Jullion, Beat Neuenschwander, Daniel Lorand BAYES2014, London, 11 June 2014 Agenda Dose escalation in oncology

More information

Innovative Analytic Approaches in the Context of a Global Pediatric IBD Drug Development

Innovative Analytic Approaches in the Context of a Global Pediatric IBD Drug Development Innovative Analytic Approaches in the Context of a Global Pediatric IBD Drug Development Margaret Gamalo-Siebers, PhD Global Statistical Sciences, Eli Lilly & Co. Pediatric Inflammatory Bowel Disease (IBD)

More information

Bayesian random-effects meta-analysis made simple

Bayesian random-effects meta-analysis made simple Bayesian random-effects meta-analysis made simple Christian Röver 1, Beat Neuenschwander 2, Simon Wandel 2, Tim Friede 1 1 Department of Medical Statistics, University Medical Center Göttingen, Göttingen,

More information

Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases

Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases Christian Röver 1, Tim Friede 1, Simon Wandel 2 and Beat Neuenschwander 2 1 Department of Medical Statistics,

More information

Bayesian Latent Subgroup Design for Basket Trials

Bayesian Latent Subgroup Design for Basket Trials Bayesian Latent Subgroup Design for Basket Trials Yiyi Chu Department of Biostatistics The University of Texas School of Public Health July 30, 2017 Outline Introduction Bayesian latent subgroup (BLAST)

More information

Designs for Basket Clinical Trials and the Exploratory/Confirmatory Paradigm

Designs for Basket Clinical Trials and the Exploratory/Confirmatory Paradigm Designs for Basket Clinical Trials and the Exploratory/Confirmatory Paradigm Richard Simon, D.Sc. R Simon Consulting rmaceysimon@gmail.com http://rsimon.us Richard Simon, D.Sc. Formerly, Director Biometric

More information

Subgroup Mixable Inference for Targeted Therapies

Subgroup Mixable Inference for Targeted Therapies Subgroup Mixable Inference for Targeted Therapies Jason C. Hsu The Ohio State University Duke Industry Statistics Symposium September 2017 In collaboration with Hong Tian, Haiyan Xu, Hui-Min Lin, Ying

More information

Basket Trials: Features, Examples, and Challenges

Basket Trials: Features, Examples, and Challenges : Features, s, and Challenges Lindsay A. Renfro, Ph.D. Associate Professor of Research Division of Biostatistics University of Southern California ASA Biopharm / Regulatory / Industry Statistics Workshop

More information

Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development. Pantelis Vlachos.

Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development. Pantelis Vlachos. Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development Pantelis Vlachos Cytel Inc, Geneva Acknowledgement Joint work with Giacomo Mordenti, Grünenthal Virginie

More information

Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center Memorial Sloan-Kettering Cancer Center Memorial Sloan-Kettering Cancer Center, Dept. of Epidemiology & Biostatistics Working Paper Series Year 2016 Paper 31 An Efficient Basket Trial Design Kristen Cunanan

More information

Statistics for Clinical Trials: Basics of Phase III Trial Design

Statistics for Clinical Trials: Basics of Phase III Trial Design Statistics for Clinical Trials: Basics of Phase III Trial Design Gary M. Clark, Ph.D. Vice President Biostatistics & Data Management Array BioPharma Inc. Boulder, Colorado USA NCIC Clinical Trials Group

More information

BORROWING EXTERNAL CONTROLS FOR AN EVENT-DRIVEN PEDIATRIC TRIAL IN PAH: A CASE STUDY

BORROWING EXTERNAL CONTROLS FOR AN EVENT-DRIVEN PEDIATRIC TRIAL IN PAH: A CASE STUDY BORROWING EXTERNAL CONTROLS FOR AN EVENT-DRIVEN PEDIATRIC TRIAL IN PAH: A CASE STUDY Adele Morganti, Matthieu Villeneuve Actelion JNJ Biostatistics Cristina Sotto, An Vandebosch JNJ SDS-SMM 1 OUTLINE Pediatric

More information

Combination dose finding studies in oncology: an industry perspective

Combination dose finding studies in oncology: an industry perspective Combination dose finding studies in oncology: an industry perspective Jian Zhu, Ling Wang Symposium on Dose Selection for Cancer Treatment Drugs Stanford, May 12 th 2017 Outline Overview Practical considerations

More information

Case Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company

Case Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company Case Studies in Bayesian Augmented Control Design Nathan Enas Ji Lin Eli Lilly and Company Outline Drivers for innovation in Phase II designs Case Study #1 Pancreatic cancer Study design Analysis Learning

More information

Media Release. Basel, 21 July 2017

Media Release. Basel, 21 July 2017 Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential

More information

Regulatory Challenges in Reviewing Oncology Product Applications

Regulatory Challenges in Reviewing Oncology Product Applications Regulatory Challenges in Reviewing Oncology Product Applications Kun He & Rajeshwari Sridhara Division of Biometrics V Office of Biostatistics Center for Drug Evaluation and Research U.S. Food and Drug

More information

Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials

Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials Amit Roy, Bristol-Myers Squibb on behalf of the PhRMA Adaptive Dose Finding Studies Working Group PharmaEd Resources Conference

More information

Statistical Considerations for Novel Trial Designs: Biomarkers, Umbrellas and Baskets

Statistical Considerations for Novel Trial Designs: Biomarkers, Umbrellas and Baskets Statistical Considerations for Novel Trial Designs: Biomarkers, Umbrellas and Baskets Bibhas Chakraborty, PhD Centre for Quantitative Medicine, Duke-NUS March 29, 2015 Personalized or Precision Medicine

More information

Using principal stratification to address post-randomization events: A case study. Baldur Magnusson, Advanced Exploratory Analytics PSI Webinar

Using principal stratification to address post-randomization events: A case study. Baldur Magnusson, Advanced Exploratory Analytics PSI Webinar Using principal stratification to address post-randomization events: A case study Baldur Magnusson, Advanced Exploratory Analytics PSI Webinar November 2, 2017 Outline Context Principal stratification

More information

Incorporating the direct assignment option into broader design frameworks

Incorporating the direct assignment option into broader design frameworks Incorporating the direct assignment option into broader design frameworks Ming-Wen An Sumithra J. Mandrekar, Daniel J. Sargent Lucy Lu Martin J. Edelman Vassar College, Poughkeepsie NY Mayo Clinic, Rochester

More information

Historical controls in clinical trials: the meta-analytic predictive approach applied to over-dispersed count data

Historical controls in clinical trials: the meta-analytic predictive approach applied to over-dispersed count data Historical controls in clinical trials: the meta-analytic predictive approach applied to over-dispersed count data Sandro Gsteiger, Beat Neuenschwander, and Heinz Schmidli Novartis Pharma AG Bayes Pharma,

More information

Evaluating Adaptive Dose Finding Designs and Methods

Evaluating Adaptive Dose Finding Designs and Methods Evaluating Adaptive Dose Finding Designs and Methods Amit Roy Bristol-Myers Squibb IIR Conference on Clinical Trial Design Princeton, NJ September 12-14, 2006 Acknowledgments: Adaptive Dose Finding Studies

More information

Designing a Bayesian randomised controlled trial in osteosarcoma. How to incorporate historical data?

Designing a Bayesian randomised controlled trial in osteosarcoma. How to incorporate historical data? Designing a Bayesian randomised controlled trial in osteosarcoma: How to incorporate historical data? C. Brard, L.V Hampson, M-C Le Deley, G. Le Teuff SCT - Montreal, May 18th 2016 Brard et al. Designing

More information

Trial design in the presence of non-exchangeable subpopulations

Trial design in the presence of non-exchangeable subpopulations Trial design in the presence of non-exchangeable subpopulations Brian P. Hobbs, PhD Cancer Biostatistics Section Head in The Taussig Cancer Institute Associate Staff, Department of Quantitative Health

More information

Fundamental Clinical Trial Design

Fundamental Clinical Trial Design Design, Monitoring, and Analysis of Clinical Trials Session 1 Overview and Introduction Overview Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics, University of Washington February 17-19, 2003

More information

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule

More information

Practical Bayesian Design and Analysis for Drug and Device Clinical Trials

Practical Bayesian Design and Analysis for Drug and Device Clinical Trials Practical Bayesian Design and Analysis for Drug and Device Clinical Trials p. 1/2 Practical Bayesian Design and Analysis for Drug and Device Clinical Trials Brian P. Hobbs Plan B Advisor: Bradley P. Carlin

More information

Rolling Dose Studies

Rolling Dose Studies PhRMA PISC Working Group on Rolling Dose Studies Results, Conclusions and Recommendations PISC Project Leaders Teleconference, July 07, 2006 Outline Goals and scope Evaluating DF methods: simulation study

More information

Adaptive Design of Affordable Clinical Trials Using Master Protocols in the Era of Precision Medicine

Adaptive Design of Affordable Clinical Trials Using Master Protocols in the Era of Precision Medicine Adaptive Design of Affordable Clinical Trials Using Master Protocols in the Era of Precision Medicine Tze Leung Lai Dept. of Statistics, Biomedical Data Science, Computational & Mathematical Engineering;

More information

Sample-size re-estimation in Multiple Sclerosis trials

Sample-size re-estimation in Multiple Sclerosis trials Novartis Basel, Switzerland Sample-size re-estimation in Multiple Sclerosis trials Heinz Schmidli PSI Meeting on Sample Size Re-Estimation London, November 2, 2016 Outline Multiple Sclerosis Sample size

More information

Phase I dose-escalation trials with more than one dosing regimen

Phase I dose-escalation trials with more than one dosing regimen Phase I dose-escalation trials with more than one dosing regimen Burak Kürşad Günhan 1 Sebastian Weber 2 Abdelkader Seroutou 2 Tim Friede 1 IBS-DR, Göttingen, 7 December, 218 1 Department of Medical Statistics,

More information

Meta-analysis of few small studies in small populations and rare diseases

Meta-analysis of few small studies in small populations and rare diseases Meta-analysis of few small studies in small populations and rare diseases Christian Röver 1, Beat Neuenschwander 2, Simon Wandel 2, Tim Friede 1 1 Department of Medical Statistics, University Medical Center

More information

Design Concept for a Confirmatory Basket Trial

Design Concept for a Confirmatory Basket Trial Design Concept for a Confirmatory Basket Trial Robert A. Beckman, MD 1 and Cong Chen, PhD 2 1 Professor of Oncology & of Biostatistics, Bioinformatics, and Biomathematics Lombardi Comprehensive Cancer

More information

Master Protocols FDA Oncology Experience

Master Protocols FDA Oncology Experience Master Protocols FDA Oncology Experience Rajeshwari Sridhara, Ph.D. Director, Division of Biometrics V Center for Drug Evaluation and Research, USFDA Outline Regulations FDA Experience with Basket, Umbrella

More information

WATCHMAN PROTECT AF Study Rev. 6

WATCHMAN PROTECT AF Study Rev. 6 WATCHMAN PROTECT AF Study Rev. 6 Protocol Synopsis Title WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Sponsor Atritech/Boston Scientific

More information

Design for Targeted Therapies: Statistical Considerations

Design for Targeted Therapies: Statistical Considerations Design for Targeted Therapies: Statistical Considerations J. Jack Lee, Ph.D. Department of Biostatistics University of Texas M. D. Anderson Cancer Center Outline Premise General Review of Statistical Designs

More information

Analysis of TB prevalence surveys

Analysis of TB prevalence surveys Workshop and training course on TB prevalence surveys with a focus on field operations Analysis of TB prevalence surveys Day 8 Thursday, 4 August 2011 Phnom Penh Babis Sismanidis with acknowledgements

More information

Current Issues in Clinical Trials A Biostatistician s perspective

Current Issues in Clinical Trials A Biostatistician s perspective Current Issues in Clinical Trials A Biostatistician s perspective Centra de Recerca Matematica CRM Seminar 10 September 2015 BARCELONA CATALUNYA Urania Dafni National and Kapodistrian University of Athens

More information

Is there a Cookbook for Oncology Clinical Trials?

Is there a Cookbook for Oncology Clinical Trials? Masterclass for Masters See beyond : An Oncology Brainstorm Ghent, 16th of September 2016 Is there a Cookbook for Oncology Clinical Trials? Dimitrios Zardavas MD Associate Scientific Director, Breast International

More information

Full title: A likelihood-based approach to early stopping in single arm phase II cancer clinical trials

Full title: A likelihood-based approach to early stopping in single arm phase II cancer clinical trials Full title: A likelihood-based approach to early stopping in single arm phase II cancer clinical trials Short title: Likelihood-based early stopping design in single arm phase II studies Elizabeth Garrett-Mayer,

More information

IMPACT OF PATIENT DIARY FORMAT ON QUALITY OF LIFE OUTCOMES IN PEOPLE WITH PARKINSON S DISEASE

IMPACT OF PATIENT DIARY FORMAT ON QUALITY OF LIFE OUTCOMES IN PEOPLE WITH PARKINSON S DISEASE Health Research Associates, inc. IMPACT OF PATIENT DIARY FORMAT ON QUALITY OF LIFE OUTCOMES IN PEOPLE WITH PARKINSON S DISEASE I. Budhiarso 1, D. Bushnell 1, M. Martin 1, and T. Hogan 2 1 Health Research

More information

In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials

In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials are comparative, large scale studies that typically

More information

Changing Patterns in Medication Use with Increasing Probability of Death for Older Medicare Beneficiaries

Changing Patterns in Medication Use with Increasing Probability of Death for Older Medicare Beneficiaries Changing Patterns in Medication Use with Increasing Probability of Death for Older Medicare Beneficiaries Thomas Shaffer, MHS; Linda Simoni-Wastila, PhD, Wendy Toler, PharmD, Bruce Stuart, PhD, and Jalpa

More information

NEED A SAMPLE SIZE? How to work with your friendly biostatistician!!!

NEED A SAMPLE SIZE? How to work with your friendly biostatistician!!! NEED A SAMPLE SIZE? How to work with your friendly biostatistician!!! BERD Pizza & Pilots November 18, 2013 Emily Van Meter, PhD Assistant Professor Division of Cancer Biostatistics Overview Why do we

More information

Information Systems Mini-Monograph

Information Systems Mini-Monograph Information Systems Mini-Monograph Interpreting Posterior Relative Risk Estimates in Disease-Mapping Studies Sylvia Richardson, Andrew Thomson, Nicky Best, and Paul Elliott Small Area Health Statistics

More information

Treatment effect estimates adjusted for small-study effects via a limit meta-analysis

Treatment effect estimates adjusted for small-study effects via a limit meta-analysis Treatment effect estimates adjusted for small-study effects via a limit meta-analysis Gerta Rücker 1, James Carpenter 12, Guido Schwarzer 1 1 Institute of Medical Biometry and Medical Informatics, University

More information

A NEW TRIAL DESIGN FULLY INTEGRATING BIOMARKER INFORMATION FOR THE EVALUATION OF TREATMENT-EFFECT MECHANISMS IN PERSONALISED MEDICINE

A NEW TRIAL DESIGN FULLY INTEGRATING BIOMARKER INFORMATION FOR THE EVALUATION OF TREATMENT-EFFECT MECHANISMS IN PERSONALISED MEDICINE A NEW TRIAL DESIGN FULLY INTEGRATING BIOMARKER INFORMATION FOR THE EVALUATION OF TREATMENT-EFFECT MECHANISMS IN PERSONALISED MEDICINE Dr Richard Emsley Centre for Biostatistics, Institute of Population

More information

Statistical Considerations in Pilot Studies

Statistical Considerations in Pilot Studies Statistical Considerations in Pilot Studies Matthew J. Gurka, PhD Professor, Dept. of Health Outcomes & Policy Associate Director, Institute for Child Health Policy Goals for Today 1. Statistical analysis

More information

Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs

Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements

More information

Bayesian graphical models for combining multiple data sources, with applications in environmental epidemiology

Bayesian graphical models for combining multiple data sources, with applications in environmental epidemiology Bayesian graphical models for combining multiple data sources, with applications in environmental epidemiology Sylvia Richardson 1 sylvia.richardson@imperial.co.uk Joint work with: Alexina Mason 1, Lawrence

More information

Trial Designs for Older Oncology Patients. Karla Ballman Division Chief and Professor of Biostatistics and Epidemiology 14 September 2018

Trial Designs for Older Oncology Patients. Karla Ballman Division Chief and Professor of Biostatistics and Epidemiology 14 September 2018 Trial Designs for Older Oncology Patients Karla Ballman Division Chief and Professor of Biostatistics and Epidemiology 14 September 2018 1 Overview Problem Endpoints Designs 2 Problem Under representation

More information

Bayesian clinical trials

Bayesian clinical trials A GUIDE TO DRUG DISCOVERY Bayesian clinical trials Donald A. Berry Abstract Bayesian statistical methods are being used increasingly in clinical research because the Bayesian approach is ideally suited

More information

Statistical, clinical and ethical considerations when minimizing confounding for overall survival in cancer immunotherapy trials

Statistical, clinical and ethical considerations when minimizing confounding for overall survival in cancer immunotherapy trials Statistical, clinical and ethical considerations when minimizing confounding for overall survival in cancer immunotherapy trials Dominik Heinzmann, PhD Global Development Team Leader HER2 Associate Director

More information

Greg Pond Ph.D., P.Stat.

Greg Pond Ph.D., P.Stat. Statistics for Clinical Trials: Basics of a Phase III Trial Design Greg Pond Ph.D., P.Stat. Ontario Clinical Oncology Group Escarpment Cancer Research Institute Department of Oncology, McMaster University

More information

A FRAMEWORK FOR SIMULATIONS IN CLINICAL RESEARCH

A FRAMEWORK FOR SIMULATIONS IN CLINICAL RESEARCH A FRAMEWORK FOR SIMULATIONS IN CLINICAL RESEARCH with applications in small populations and rare diseases Tim Friede 1, Norbert Benda 2 1 University Medical Center Göttingen, Göttingen, Germany 2 Federal

More information

How to select study subjects using Sampling Technique

How to select study subjects using Sampling Technique How to select study subjects using Sampling Technique Objectives: To understand: Why we use methods Definitions of few concepts Sampling and non- methods And able to use methods appropriately Team Members:

More information

Biomarkers in oncology drug development

Biomarkers in oncology drug development Biomarkers in oncology drug development Andrew Stone Stone Biostatistics Ltd EFSPI Biomarkers and Subgroups June 2016 E: andrew@stonebiostatistics.com T: +44 (0) 7919 211836 W: stonebiostatistics.com available

More information

The questions are changing in early phase cancer clinical trials: Opportunities for novel statistical designs

The questions are changing in early phase cancer clinical trials: Opportunities for novel statistical designs The questions are changing in early phase cancer clinical trials: Opportunities for novel statistical designs Elizabeth Garrett-Mayer, PhD Associate Professor Director of Biostatistics, Hollings Cancer

More information

XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.

XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral

More information

(Regulatory) views on Biomarker defined Subgroups

(Regulatory) views on Biomarker defined Subgroups (Regulatory) views on Biomarker defined Subgroups Norbert Benda Disclaimer: Views expressed in this presentation are the author's personal views and not necessarily the views of BfArM Biomarker defined

More information

How to select study subjects using Sampling Technique

How to select study subjects using Sampling Technique How to select study subjects using Sampling Technique Objectives: To understand: Why we use methods Definitions of few concepts Sampling and non- methods And able to use methods appropriately Team Members:

More information

WAKE-UP has received funding from the European Union Seventh Framework Programme (FP7/ ) under grant agreement n

WAKE-UP has received funding from the European Union Seventh Framework Programme (FP7/ ) under grant agreement n Intravenous Thrombombolysis in Stroke Patients with Unknown Time of Onset Results of the Multicentre, Randomized, Double-blind, Placebo- Controlled WAKE-UP Trial G. Thomalla, C.Z. Simonsen, F. Boutitie,

More information

Summary... 2 IMMUNOTHERAPY IN CANCER... 3

Summary... 2 IMMUNOTHERAPY IN CANCER... 3 ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 IMMUNOTHERAPY IN CANCER... 3 Sequencing analysis reveals baseline tumour T cell receptor and neo antigen load associates

More information

Bayes-Verfahren in klinischen Studien

Bayes-Verfahren in klinischen Studien Bayes-Verfahren in klinischen Studien Dr. rer. nat. Joachim Gerß, Dipl.-Stat. joachim.gerss@ukmuenster.de Institute of Biostatistics and Clinical Research J. Gerß: Bayesian Methods in Clinical Trials 2

More information

Department of International Health

Department of International Health JOHNS HOPKINS U N I V E R S I T Y Center for Clinical Trials Department of Biostatistics Department of Epidemiology Department of International Health Memorandum Department of Medicine Department of Ophthalmology

More information

Dawson James Conference

Dawson James Conference Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding

More information

Evolution of Early Phase Trials: Clinical Trial Design in the Modern Era

Evolution of Early Phase Trials: Clinical Trial Design in the Modern Era Evolution of Early Phase Trials: Clinical Trial Design in the Modern Era Shivaani Kummar, MD, FACP Professor of Medicine (Oncology) Director, Phase I Clinical Research Program Co-Director, Translational

More information

Statistical Challenges for Novel Technologies. Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute

Statistical Challenges for Novel Technologies. Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute Statistical Challenges for Novel Technologies Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute ISCTM 2016 Autumn Conference, Philadelphia, PA 27 September

More information

Bayesian Meta-Analysis in Drug Safety Evaluation

Bayesian Meta-Analysis in Drug Safety Evaluation Bayesian Meta-Analysis in Drug Safety Evaluation Amy Xia, PhD Amgen, Inc. BBS Meta-Analysis of Clinical Safety Data Seminar Oct 2, 2014 Disclaimer: The views expressed herein represent those of the presenter

More information

Statistical controversies in clinical research: building the bridge to phase II efficacy estimation in dose-expansion cohorts

Statistical controversies in clinical research: building the bridge to phase II efficacy estimation in dose-expansion cohorts Annals of Oncology 28: 1427 1435, 17 doi:10.1093/annonc/mdx045 Published online 13 February 17 SPECIAL ARTICLE Statistical controversies in clinical research: building the bridge to phase II efficacy estimation

More information

Frédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018

Frédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018 Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress

More information

Jan Bogaerts Scientific Director EORTC Headquarters Belgium

Jan Bogaerts Scientific Director EORTC Headquarters Belgium What defines the disease and populations? How to deal with large subgroups within an indication? Heterogeneity, lack of historical real-life data, rarest subtypes Jan Bogaerts Scientific Director EORTC

More information

Media Release. Basel, 07 December 2017

Media Release. Basel, 07 December 2017 Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent

More information

Biostatistical modelling in genomics for clinical cancer studies

Biostatistical modelling in genomics for clinical cancer studies This work was supported by Entente Cordiale Cancer Research Bursaries Biostatistical modelling in genomics for clinical cancer studies Philippe Broët JE 2492 Faculté de Médecine Paris-Sud In collaboration

More information

Population Enrichment Designs Case Study of a Large Multinational Trial

Population Enrichment Designs Case Study of a Large Multinational Trial Population Enrichment Designs Case Study of a Large Multinational Trial Harvard Schering-Plough Workshop Boston, 29 May 2009 Cyrus R. Mehta, Ph.D Cytel Corporation and Harvard School of Public Health email:

More information

Analysis methods for improved external validity

Analysis methods for improved external validity Analysis methods for improved external validity Elizabeth Stuart Johns Hopkins Bloomberg School of Public Health Department of Mental Health Department of Biostatistics www.biostat.jhsph.edu/ estuart estuart@jhsph.edu

More information

Introduction to Meta-analysis of Accuracy Data

Introduction to Meta-analysis of Accuracy Data Introduction to Meta-analysis of Accuracy Data Hans Reitsma MD, PhD Dept. of Clinical Epidemiology, Biostatistics & Bioinformatics Academic Medical Center - Amsterdam Continental European Support Unit

More information

Building AlLIAnces in Placer County

Building AlLIAnces in Placer County Building AlLIAnces in Placer County Presented by the Placer SNAP-Ed Coordinating Council (PSCC) to the 2016 Supplemental Nutrition Assistance Program-Education (SNAP-Ed) Local Implementing Agency (LIA)

More information

CLINICAL PROTOCOL DEVELOPMENT

CLINICAL PROTOCOL DEVELOPMENT CLINICAL PROTOCOL DEVELOPMENT Clinical Protocol (1) Background/Justification --Where we are in the field --What the study will add that is important Objectives --Primary hypothesis --Secondary hypotheses

More information

Surveillance strategies for Foot and Mouth Disease to prove absence from disease and absence of viral circulation

Surveillance strategies for Foot and Mouth Disease to prove absence from disease and absence of viral circulation Surveillance strategies for Foot and Mouth Disease to prove absence from disease and absence of viral circulation Vincenzo Capora Asuncion, 25 June 20 Introduction In FMD control the need to prove absence

More information

CHAPTER 3 METHOD AND PROCEDURE

CHAPTER 3 METHOD AND PROCEDURE CHAPTER 3 METHOD AND PROCEDURE Previous chapter namely Review of the Literature was concerned with the review of the research studies conducted in the field of teacher education, with special reference

More information

Bayesian methods for combining multiple Individual and Aggregate data Sources in observational studies

Bayesian methods for combining multiple Individual and Aggregate data Sources in observational studies Bayesian methods for combining multiple Individual and Aggregate data Sources in observational studies Sara Geneletti Department of Epidemiology and Public Health Imperial College, London s.geneletti@imperial.ac.uk

More information

Third Quarter 2015 Earnings Call. November 9, 2015

Third Quarter 2015 Earnings Call. November 9, 2015 Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

Ureteroscopic treatment of renal stones: Dusting vs Extraction

Ureteroscopic treatment of renal stones: Dusting vs Extraction Ureteroscopic treatment of renal stones: Dusting vs Extraction Khurshid Ghani Dept of Urology Will Meurer Depts of Emergency Medicine and Neurology University of Michigan Background Use of flexible ureteroscopy

More information

The Exposure-Stratified Retrospective Study: Application to High-Incidence Diseases

The Exposure-Stratified Retrospective Study: Application to High-Incidence Diseases The Exposure-Stratified Retrospective Study: Application to High-Incidence Diseases Peng T. Liu and Debra A. Street Division of Public Health and Biostatistics, CFSAN, FDA 5100 Paint Branch Pkwy, College

More information

For general queries, contact

For general queries, contact Much of the work in Bayesian econometrics has focused on showing the value of Bayesian methods for parametric models (see, for example, Geweke (2005), Koop (2003), Li and Tobias (2011), and Rossi, Allenby,

More information

Design and analysis of clinical trials

Design and analysis of clinical trials Design and analysis of clinical trials Lecture 3 1.Basic Design Considerations 2.Sample Size determinationa 3.Randomization 2018-01-31 Previous Lectures Definition of a clinical trial The drug development

More information

Media Release. Basel, 20 March 2018

Media Release. Basel, 20 March 2018 Media Release Basel, 20 March 2018 Phase III IMpower131 study showed Roche s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the

More information

Appendix A Survey on CDC s Guidelines for Infection Control in Dental HealthCare Settings 2003

Appendix A Survey on CDC s Guidelines for Infection Control in Dental HealthCare Settings 2003 SUPPLEMENTAL DATA Appendix A Survey on CDC s Guidelines for Infection Control in Dental HealthCare Settings 2003 Cleveland JL et al. JADA 2012;143(10):1127-1138 Supplemental Data 1 Cleveland JL et al.

More information

Practitioner s Guide To Stratified Random Sampling: Part 1

Practitioner s Guide To Stratified Random Sampling: Part 1 Practitioner s Guide To Stratified Random Sampling: Part 1 By Brian Kriegler November 30, 2018, 3:53 PM EST This is the first of two articles on stratified random sampling. In the first article, I discuss

More information

Estimands. EFPIA webinar Rob Hemmings, Frank Bretz October 2017

Estimands. EFPIA webinar Rob Hemmings, Frank Bretz October 2017 Estimands EFPIA webinar Rob Hemmings, Frank Bretz October 2017 Why estimands? To explain which treatment effect is described to prescribers and other stakeholders. To align objectives with (design and)

More information

Clinical Trial Design to Expedite Drug Development Mary W. Redman, Ph.D.

Clinical Trial Design to Expedite Drug Development Mary W. Redman, Ph.D. Clinical Trial Design to Expedite Drug Development Mary W. Redman, Ph.D. What do we mean by expediting drug development? Phase I Single Arm Phase II (expansion cohort) Randomized Phase II Phase III Necessary?

More information

Sensitivity of heterogeneity priors in meta-analysis

Sensitivity of heterogeneity priors in meta-analysis Sensitivity of heterogeneity priors in meta-analysis Ma lgorzata Roos BAYES2015, 19.-22.05.2015 15/05/2015 Page 1 Bayesian approaches to incorporating historical information in clinical trials Joint work

More information

EXTRAPOLATION CHALLENGES IN PEDIATRIC PAH

EXTRAPOLATION CHALLENGES IN PEDIATRIC PAH EXTRAPOLATION CHALLENGES IN PEDIATRIC PAH Possible solutions for a feasible, global study M. Bacchi, A. Morganti, P. Cornelisse, J. Bolognese, C. Lesage, A. Kümmel, P. Nilsson Copyright 2016 Actelion Pharmaceuticals

More information